MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0).

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has provided an update of its natural plant-based, mustard-derived biopesticide technology product pipeline. The company is intent on using the natural defense mechanism of the mustard seed to develop and commercialize biopesticide technologies; MustGrow is using the technology to control diseases, pests and weeds. The company is planning a live investor webcast today to discuss upcoming catalysts; the webcast is slated to begin at 11 a.m. ET. Anyone interested in attending should sign in five minutes early. To attend the live webcast, visit http://ibn.fm/xtPRT. To view the full press release, visit http://ibn.fm/2MUNq.

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding.

Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests like nematodes. This company’s all-natural, effective, safe and easy-to-use solution is ideal for farmers looking to raise healthy crops without chemical pesticides amid growing concerns worldwide over the negative effects of chemical pesticide solutions.

MustGrow, which went public in 2019, was founded in Saskatoon, Canada, and is currently focused on disrupting the $65 billion global pesticide market with its 100% owned and patented mustard-derived technology. Canada produces 28% of the global mustard crop and is the world’s largest exporter, with a 57% market share.

TerraMG and Pipeline

The company’s technology extracts the mustard plant’s natural organic compounds, which, when combined with water, form Allyl isothiocyanate (AITC) and serve as a natural defense mechanism for the plant against pests and diseases. MustGrow’s mustard-derived technology acts as both a natural bio-pesticide and as a non-selective bio-herbicide.

There are currently more than 110 independent third-party trials that confirm the safety and efficacy of MustGrow’s solutions, potentially positioning the company as a leading provider of safe plant protection solutions in a market that is gradually eliminating the use of chemical compounds.

MustGrow’s primary product at the moment is the new liquid formulation TerraMG, which has the potential to compete against existing chemistries on both efficacy and price. Its initial target market is as a pre-plant soil bio-pesticide for use with higher-value crops such as fruits and vegetables. This liquid formulation is safe and easy to transport and has already demonstrated its efficacy against several pests and diseases.

In addition to its use as a pre-plant soil treatment, TerraMG has significant potential for multiple applications in several other markets, which is expected to aggressively expand the company’s IP portfolio. MustGrow has already confirmed or is in the process of testing multiple applications of TerraMG, including fruit and vegetable soil fumigation ($1.2 billion estimated global market), container fumigation ($2 billion estimated global market), tobacco nematode and disease fumigation ($4 billion estimated global loss), non-selective herbicide ($13 billion estimated global market), food-borne pathogens ($15 billion estimated global market) and more.

The company anticipates registration approval for the liquid formulation (TerraMG) as a pre-plant bio-pesticide for soil-borne diseases and pests from the EPA (United States) and PMRA (Canada) in 2021. The company already has EPA and PMRA approval for the product’s granular form.

Currently, MustGrow’s pipeline also includes:

• TerraMG, a pre-plant soil bio-pesticide, for:
  • Fruit & Vegetable – currently in Phase 4
  • Turf & Ornamental – currently in Phase 4
  • Tobacco – currently in Phase 4
  • Potatoes – currently in Phase 4
  • Canola – targeting Clubroot Disease – currently in Phase 3: Advanced Development/Field Trials
  • Bananas – targeting Fusarium wilt TR4 – currently in Phase 1: Proof of Concept/Laboratory
  • Pulse Crops – targeting Aphanomyces – currently in Phase 1: Proof of Concept/Laboratory
• Non-Selective Bio-Herbicide – targeting noxious or resistant weeds – currently in Phase 2: Early Development/Greenhouse
• Storage Bio-Pesticide for Bulk Grain, Fresh Produce – targeting toxins, diseases and insects – currently in Phase 1: Proof of Concept/Laboratory
• Storage Bio-Pesticide for Shipping Containers – targeting fungus, invasive pests and diseases – currently in Phase 1: Proof of Concept/Laboratory
• Bio-Pesticide for Foodborne Pathogens – targeting E. coli, salmonella, Listeria, human pathogens, etc. – currently in Phase 1: Proof of Concept/Laboratory

Market Opportunity

The protection of crops with synthetic chemical pesticides represents a $65 billion-dollar global market that is expected to grow in the coming years as the global population grows and needs more food. This number doesn’t include bio-pesticide sales, which are projected to increase to $8.5 billion by 2025, with a CAGR of 14.7%. MustGrow, with its natural bio-pesticide, is targeting not only the bio-pesticide market, but also the global synthetic chemical market so as to help replace harmful synthetic pesticides and provide a natural biologic that has the efficacy of controlling pests and disease compared to synthetic chemicals in some instances.

Management Team

Corey Giasson is the President, CEO and Director of MustGrow. He is an entrepreneur focused on the agriculture, mining, real estate and oil/gas industries, primarily in the Canadian province of Saskatchewan. Giasson is co-founder and director of Legacy Capital Corp. This private equity company focuses on participating in management buyouts of strong, sustainable cash flowing businesses. He has an MBA and B.Sc. in Agriculture Economics from the University of Saskatchewan.

Colin Bletsky is COO and Director of MustGrow. He grew up in Eastern Saskatchewan on his family’s third-generation farm, growing canola, wheat and oats. The majority of his time is spent helping other organizations and farmers grow their businesses – locally and globally. Bletsky has a Bachelor of Science in Agriculture from the University of Saskatchewan and executive education from the London School of Business and INSEAD.

Todd Lahti is the company’s CFO. He has extensive experience evaluating and managing biotech, agricultural and oil/gas start-up companies by working directly on financing transactions, mergers and acquisitions, business development, corporate strategy, technology transfer and operations setup. Lahti is a Chartered Financial Analyst and a Chartered Professional Accountant.

Brad Munro is Chairman of MustGrow. He is the President and CEO of Bittercreek Capital Corp., a private investment and advisory firm. He has extensive corporate finance and investment experience in the natural gas and oil industries, among others. Munro has a Bachelor of Commerce from the University of Saskatchewan.

MustGrow Biologics Corp. (OTCQB: MGROF), closed Wednesday's trading session at $0.80, up 12.6761%, on 65,410 volume with 18 trades. The average volume for the last 3 months is 13,704 and the stock's 52-week low/high is $0.009999999/$0.944999992.

Recent News

• BioMedNewsBreaks - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Live Investor Webcast; Provides Overview of Biopesticide Pipeline
• BioMedNewsBreaks - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Upcoming Investor Webcast
• MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Obtains Patent for Mustard-Derived Fumigation of Stored Vegetables, Grains

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. To view the full press release, visit http://ibn.fm/Swa22

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $2.58, up 5.3061%, on 233,981 volume with 799 trades. The average volume for the last 3 months is 47,393 and the stock's 52-week low/high is $1.25820004/$5.61999988.

Recent News

• BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes 'Most Exciting Thing That I've Done' on Gamechangers LIVE
• BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial
• CNS Pharmaceuticals (NASDAQ: CNSP) Advances Brain Cancer Drug Candidate and Sponsors Annual SNO Conference

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF)

The QualityStocks Daily Newsletter would like to spotlight LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF).

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Dr. Jack Regan, LexaGene’s CEO and founder, will present at the 13th Annual LD Micro Main Event Conference. Interested parties should visit https://ibn.fm/tKpNj to register for the event, slated to be held on Dec. 15, 2020. To view the full press release, visit http://ibn.fm/bF2XE

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) is a molecular diagnostics company that develops genetic analyzers for rapid detection of pathogens at the point-of-need.

Based in the greater-Boston, Massachusetts area, the company’s fully automated genetic analyzer for pathogen detection, the MiQLab™, is designed to deliver reference-quality data with ease of use. MiQLab’s technology screens samples for up to 27 different targets at once—looking for pathogens and antimicrobial resistance factors—and returns results in approximately one hour. It is designed to be operated at the site of sample collection to avoid the delay associated with shipping and manually processing samples. This technology is designed for use in multiple markets, including human and veterinary diagnostics, as well as food safety testing ($12.9B, $2.2B, and $23.4B markets, respectively).

Portfolio Benefits

Rapid, automated pathogen detection

LexaGene’s MiQLab pathogen detection system offers rapid and sensitive testing to markets in need of better vigilance against pathogens that could endanger health and harm public safety and the bottom line. The company’s disruptive technology is on-demand and offers results in approximately an hour.

End users collect a sample, load it onto the MiQLab genetic analyzer with a sample preparation cartridge, enter a sample ID and press ‘go’.

MiQLab is open-access, which allows users to easily customize their own tests, in addition to running the company’s own validated tests. No comparable technology exists on the market today for automating customized testing. The open-access market is over $20 billion in value and includes industries like pharma and biotech that currently need an automated method of performing PCR testing in a cost-efficient way.

Improved COVID-19 Testing

As the COVID-19 pandemic continues to pose a threat to global safety, the need for improved testing procedures has been well established. LexaGene’s technology is automated and designed to be used at the point-of-need, thereby avoiding the 12- to 24-hour shipping time. Plus, it performs sample preparation and the gold standard RT-PCR chemistry for exceptional data quality in about one hour.

Because LexaGene’s open-access instrument can be rapidly configured to detect novel pathogens, it is ideally suited to prevent pandemic spread with its easily deployed testing that facilitates rapid quarantine-related decision making.

This speed is in stark contrast to competitor point-of-care technologies that have reagents pre-embedded into complex and expensive cartridges that are only manufactured at specialized production sites — making it impossible to rapidly meet a swift increase in demand.

According to Dr. Jack Regan, LexaGene’s CEO and founder, the world needs easy-to-use, fully automated pathogen detection instruments operating at points-of-need that can be equipped with tests to detect a novel pathogen within a week of knowing its genetic sequence. For this pandemic, the lack of such technology forced the majority of testing to occur in distant reference laboratories, making rapid decisions on quarantine impossible and making the likelihood of successful containment remote.

Regan explained in a press release (http://nnw.fm/Vz5Ju), “LexaGene expects to be the first company to commercialize an automated open-access microfluidic technology designed for use at the point-of-need that can be configured to detect a novel pathogen in just a week’s time of its emergence — for use on-site to return results in one hour — and improve our chances of successful containment.”

Market Potential

LexaGene’s technology has a wide range of applications across many other markets, including biotech and pharma testing, water quality monitoring, agricultural testing, biodefense, and use at point-of-need at border crossings, military bases, aircraft carriers and cruise ships.

Markets for customized testing solutions are poised for significant growth. Industry analysts forecast considerable expansion of many of LexaGene’s potential target markets in the coming years, including:

• The genotyping sector, forecast to reach a valuation of $31.9 billion by 2023;
• PCR assays, expected to make up a $7 billion market opportunity by 2026;
• The sample prep market, forecast to eclipse $9.3 billion by 2025;
• Water quality monitoring, set to grow to $1.59 billion by 2022; and
• Agricultural testing, anticipated to reach $6.29 billion by 2022.

LexaGene’s patented microfluidic system was invented by company CEO Regan, a leading scientist who developed a bio-warfare surveillance instrument that has been adopted by the Department of Homeland Security. Regan is also known for developing an instrument that detects respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20 million in government funding.

Management Team

LexaGene’s experienced leadership team drives company growth with a focus on innovation, pursuing unique market opportunities and providing shareholder value.

Dr. Jack Regan, Chief Executive Officer & Director, is the inventor of the company’s flagship automated pathogen detection technology, the MiQLab. Before founding LexaGene, he led a team of scientists at Bio-Rad Laboratories (NYSE: BIO) in developing tests for detecting pathogens, cancer and neurological disorders using droplet digital PCR. Prior to Bio-Rad, Regan helped QuantaLife, a startup company, bring its product from concept to commercialization, where it was subsequently acquired by Bio-Rad. He has also worked at Applied Biosystems/Life Technologies on automated sample preparation and did his post-doctoral training at Lawrence Livermore National Laboratory. His doctoral training at the University of California San Francisco focused on influenza viral replication.

Daryl Rebeck, President, has over 20 years of capital market experience with an established international financial network. Rebeck was a vice president and senior investment advisor with Canada’s largest independent investment bank, Canaccord Genuity, where he was responsible for raising significant risk capital for growth companies, with a particular focus on natural resources and medical technology. He has since worked to provide management expertise and grow shareholder value. He served as senior VP of corporate finance of Auryn Resources (NYSE: AUG), a $250 million market cap mining exploration company.

Jeffrey Mitchell, CFO, boasts over two decades of financial and SEC experience. Before joining LexaGene, he served as controller and director of finance, overseeing areas such as public company financial reporting, audits, and financial planning and analysis for Palomar Medical Technologies Inc. In addition to his many years at Palomar, Mitchell has served in numerous financial and strategic advisory roles for medical device, imaging and diagnostic companies.

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF), closed Wednesday's trading session at $0.6485, up 2.9365%, on 312,693 volume with 121 trades. The average volume for the last 3 months is 237,333 and the stock's 52-week low/high is $0.303799986/$0.928245007.

Recent News

• BioMedNewsBreaks - LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Participate at LD Micro Main Event
• BioMedNewsBreaks - LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Places MiQLab(TM) System in Penn Vet Microbiology Laboratory
• LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Annual General Shareholder's Meeting Results, Secures Order for MiQLab(TM) System

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative solutions for the worldwide life science and other industries, recently reported its third-quarter financial results and provided a business update, which included initial expectations for 2021 (https://ibn.fm/8PNFi). Among the updates, the Q3 2020 Form 10-Q financial report outlines measurable progress in three important areas: key operational and technical projects; revenue increases in the company’s products and services offerings; and important structuring improvements in the reduction of arduous, variable-rate convertible debt. To view the full article, visit https://ibn.fm/rmySv

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $2.25, up 2.2727%, on 13,699 volume with 39 trades. The average volume for the last 3 months is 22,084 and the stock's 52-week low/high is $0.600600004/$4.48999977.

Recent News

• InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) on Track to Launch BaroShear K45 Nanoemulsification System in 2021
• InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Announces Commercial Launch Date for ImmunaZin(TM)
• InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Looks to Provide Key to Commercial Success of Novel Products

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from BioMedWire, examining how scientists at the Georgia State University Institute for Biomedical Sciences have found that the MK-4482/EIDD-2801 antiviral drug, which was developed to treat the SARS-CoV-2 infection, completely stops transmission of the virus in 24 hours. Also today, the company was featured in a publication from BioMedWire, examining how POAI today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote in favor of the proposals being considered at the special meeting, primarily because the reincorporation in Nevada will eliminate its obligation to pay the injurious annual Delaware franchise tax, currently equal to approximately $170,000 per year. Predictive Oncology can save approximately $158,000 annually in state taxes by reincorporating in Nevada. To view the full press release, visit: https://ibn.fm/wMinE

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

• A database of clinically validated historical and outcome data from patient tumors
• An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
• A “smart” patient-derived tumor profiling platform
• An in-house bioinformatics artificial intelligence (AI) platform
• A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
• An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Wednesday's trading session at $0.7573, up 8.6358%, on 4,193,857 volume with 5,462 trades. The average volume for the last 3 months is 1,051,796 and the stock's 52-week low/high is $0.629999995/$5.30000019.

Recent News

• Georgia State Researchers Develop Drug That Can Stop Coronavirus Transmission
• BioMedNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting
• BioMedNewsBreaks - Predictive Oncology Inc.'s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations

ISW Holdings (ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings (ISWH).

ISW Holdings (OTC: ISWH), a global brand management holdings company, has reached an agreement with its largest noteholders to exchange approximately 50% of its current convertible debt for restricted preferred equity. The agreement eliminates a significant portion of the dilution potential from convertible debentures currently carried by ISW Holdings. To view the full press release, visit http://ccw.fm/Fhd6K

ISW Holdings (ISWH) (“ISW Holdings”) is a brand management portfolio company with diverse partnerships that focus on growing businesses in multiple sectors, including crypto mining, renewable energy, home health care for the chronically ill, wellness and restoration, and the adult beverage industry, as well as early-stage operations in supply chain and logistics management. ISW Holdings operates as the nexus between its partnerships and their essential services for end users.

Mission
The company’s core mission is to enhance these sectors by implementing innovative services and products ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources, and innovative software to establish market-leading companies and partnerships, which ensure their success in their chosen industries. This enables the company to return maximum shareholder value with its focus always on its partnerships’ various sector volatility.

The Revolution
Positioned to create industry leaders, the company’s process entails strategic development and aggressive early growth of its partner brands to establish them as profitable and viable. ISW Holdings’ method is to nurture emerging partner brands through the essential stages of market development (from conceptualization to distribution) in sectors relevant to today’s marketplace. In addition, the company has a holistic approach to business development, with every strategy being delivered person-to-person from developers to end users.

The Challenge
The company’s goal is to turn its target audience into loyal consumers by ensuring transparency and a clear understanding of its products and services, thus creating visibility, credibility, and trust.

ISW Holdings’ Innovative Approach
ISW Holdings has diversified positions in its partnerships across technology, health care, wellness, renewable energy, and the adult beverage sectors. The company seek to provide industry leading modern solutions to its clients and sound business practices to its partners. This is accomplished through an early growth platform that cultivates its partnerships with the necessary resources and expertise to expand exponentially.

ISW Holdings’ Opportunity
The company’s opportunity is considerable. In the ever-changing high demand global marketplace, the need for timely innovation is critical. ISW Holdings’ portfolio brand management and creative thinking has allowed the company to develop and deploy enterprises that meet the needs of 21st century consumers. Through a fully vetted system of scalability, it is able to meet consumer demands with turn-key solutions.

Portfolio of Partnerships and Businesses
ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. With partnerships that incorporate a depth of experience and industry insight, ISW Holdings has established itself as a portfolio company in technology, home health care, and wellness, with a focus on reshaping industry benchmarks.

Bit5ive

ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. As an official distribution partner of Bitmain (the industry’s leading fabless manufacturer of computing chips and distributor of Antminers to more than 30 countries in Latin America, Central America, and the Caribbean), Bit5ive is quickly becoming one of the largest U.S.-based companies in the cryptocurrency mining and bitcoin farm sectors of the market.
Valued at $293.66 million in 2019, the bitcoin technology market is expected to reach $477 million by 2025, according to Mordor Intelligence. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.

Proceso, LLC

With a growing awareness of the importance of renewable energy worldwide, ISW Holdings has partnered with Proceso, LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining — two fields with a typically high energy demand.

Because crypto mining companies mostly operate outside of the United States with higher asset security risks, Proceso will assist these entities in securing their investments by providing a local source of power and infrastructure development. This is aimed at helping to reduce power consumption while creating secure crypto mining data centers in the U.S. For the gaming industry, Proceso is ready to tackle one of its biggest problems, latency, by building next-level infrastructure in key locations.

PHH — Home Health

PHH Paradigm Home Health answers the growing need for homecare services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care. PHH aims to be at the forefront of this change by offering quality care services infused with new emerging technologies.

ISW Holdings’ home health division is currently developing a pilot for on-demand health care, which consists of a dedicated, stable platform for different medical services. The platform will offer greater freedom of choice and transparency by allowing users to find outpatient clinics in their vicinities, compare costs, and pick the most suitable choices. PHH is also developing specialized technology and tools to support health care services outside of the bounds of specialized facilities by focusing on homecare facilities. This can not only shift the burden from hospitals and clinics, but also streamline specific parts of the health care process to enhance service and product distribution.

VOLUM

ISW Holdings’ logistics and supply chain management division was designed with the core goal of increasing supply chain efficiency as one of the key aspects of successfully growing any business. The VOLUM project’s focus is on identifying and then implementing advanced supply chain management strategies and methods that will enable ISW Holdings’ partner companies to scale and grow exponentially. To achieve this goal, the company develops and offers reliable systems and solutions that create innovative technologies and unmanned system operations for overall higher cost-effectiveness.

In the wellness sector, ISW Holdings has opted for a two-pronged approach to create effective, technologically advanced products, as well as developing innovative ways to educate customers about these products. To this end, ISW Holdings has partnered with BioPulse to achieve state-of-the-art research and development and production capabilities, as well as a direct route to market. The company plans to design and launch up to five unique brands in the wellness and restoration sector in 2020.

ISW Holdings is committed to developing product and service innovation in the consumer spirits and adult beverage industry, which faces increasingly strict regulations but growing demand. The company has been a key innovator in the industry for 25 years, having grown successful luxury brands such as Besado Tequila and others. By leveraging its expertise, ISW Holdings can help companies in the adult beverage industry increase production, streamline their supply chains, implement better processes, innovate their marketing strategies, expand into new areas, and build sustainable relationships with partners and customers.

Management Team

Terry Williams, Chief Executive Officer and Director
Terry Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance, and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, Williams amassed considerable corporate experience at United Parcel Service, where he took several logistical roles, including controller, where he managed more than 2,000 employees and a budget of more than $10 billion.

Williams also serves as president of Airwave Transportation and logistics and chief financial officer of AVI Insurance Caribbean, and he has worked in over 37 domestic and international airports. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce, Chairman
Alonzo Pierce is chairman of ISW Holdings and brings a wealth of business development and wealth management experience to the ISW team. He has spent the past 20 years building recognizable brands in multiple industry sectors. He has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands, including selling the world’s only black vodka. He served as regional director for Sapphire Brands, covering the Southwest and Southeast regions. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown, Secretary, Treasurer, Director
Kristina Mahoney-Brown is secretary and treasurer as well as director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings (ISWH), closed Wednesday's trading session at $0.0701, up 7.8462%, on 2,395,530 volume with 252 trades. The average volume for the last 3 months is 2,269,742 and the stock's 52-week low/high is $0.0152/$1.50.

Recent News

• CryptoNewsBreaks - ISW Holdings Inc. (ISWH) Announces Agreement with Noteholders to Reduce Debt
• CryptoNewsBreaks - ISW Holdings Inc. (ISWH) Moves to Deployment Phase of State-of-the-Art Crypto Mining Solution
• CryptoNewsBreaks - ISW Holdings Inc. (ISWH) Achieves 57% Topline Growth in Third Quarter

RYAH Group Inc.

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc..

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

RYAH Group Inc. is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

Investment Considerations

• RYAH Group is a technological leader in the plant-based treatment market with its unique combination of proprietary IoT devices and data analytics, supported by patented AI technology.
• The company’s products pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services.
• RYAH offers a complete remote dosage delivery and dose-monitoring platform based on data-driven analytics supported by prescribing doctors and their patients.
• The company is finalizing its anticipated listing on the Canadian Securities Exchange.
• RYAH holds a unique position on the $100.3 billion medical plant market, with the potential to capture footholds in both the IoT and Data Intelligence industries.

Recent News

• RYAH Group Inc. Is ‘One to Watch’
• RYAH Enters into Merger Agreement with Prime Blockchain in respect of Previously Announced Proposed Reverse Takeover
• RYAH Medtech Inc. And ARGOS-Applied Intelligence Sign MOU to Advance Data Analytics In Plant-Based Medicine

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, will be hosting the 13th Annual LD Micro Main Event on December 14-15, 2020 via its Sequire Virtual Events SaaS platform. Over 250 companies are scheduled to present to a potential audience of over 2 million invited guests. Attendees will have exclusive access to interviews with Shaquille O'Neal and 2020 presidential candidate Brock Pierce along with other influential panelists across the small-cap space.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

• SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
• SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
• SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
• SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
• SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
• SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $2.48, off by 3.876%, on 113,523 volume with 478 trades. The average volume for the last 3 months is 77,551 and the stock's 52-week low/high is $1.26429998/$3.35739994.

Recent News

• SRAX Inc. (NASDAQ: SRAX) To Host LD Micro's 13th Annual Main Event on Sequire Platform, Speakers Include Shaquille O'Neal & Brock Pierce
• SRAX Inc.'s (NASDAQ: SRAX) Sequire Software Helps Public Companies Gain Clarity Amid "Gut-Wrenching" Stock Market Volatility
• InvestorNewsBreaks - SRAX Inc. (NASDAQ: SRAX) to Feature Keynote Speakers Shaquille O'Neal and Brock Pierce at LD Micro Main Event

Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF)

The QualityStocks Daily Newsletter would like to spotlight Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF).

Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced its entry into a memorandum of understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to support specific near-term opportunities with world renown resorts, national tourism boards, major airlines, airports, cruise ships, and ports. To view the full press release, visit https://ibn.fm/1alw7

Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF) is an innovative technology company leveraging Internet of Things (IoT) technologies to deliver contactless solutions, including its venue management platform, personalized engagement services and AI-driven insights.

The company was founded on June 12, 2019, and is headquartered in Vancouver, Canada. Loop is currently offering its solutions to major players in the telecom, sports, casino gaming, hospitality, entertainment and retail industries across Canada, the United States, South America, the UK, Australia, Indonesia and Japan.

Scaled and Fully Managed Services

Loop Insights has integrated both its Fobi and SmarTap devices with its proprietary cloud to provide end-to-end services for the retail, travel, entertainment and hospitality industries.

Loop’s Automated Venue Management Platform

Loop’s venue management platform is a fully managed contactless check-in platform that securely aggregates venue and visitor information in order to generate real-time feedback to both venue hosts and consumers. Loop’s venue management platform can be applied to venue tracing for COVID-19 or used in traditional environments for applications in ticketing, retail and hospitality.

Loop’s COVID-19 Venue Tracing Solution

Loop Insights is committed to leveraging its solutions for COVID-19 management, allowing for easier tracing, testing and data collection.

Loop Insights has adapted its existing technology to create a venue management platform designed specifically for tracing the COVID-19 pandemic. The company’s complete end-to-end COVID-19 management platform provides a means for venues and event hosts to manage attendees and instantly trace and notify potential at-risk visitors.

Loop Insights has partnered with a number of medical testing companies including iSTOC and Empower Clinics to provide rapid testing options wherever its COVID-19 venue management system is deployed.

Loop Insights signed a referral and partnership agreement with Finland’s iSTOC Ltd. in November 2020, providing the company COVID-19 testing and integrated lab capabilities in Europe. The partnership allows Loop to provide FDA and HIPAA-compliant tracing and testing that can be deployed by any health care organization, NGO or government worldwide. “Our partnership with iSTOC positions us as a true global leader regarding complete COVID-19 management solutions,” Loop Insights CEO Rob Anson explained.

Through its partnership with Summit Services Inc., Loop Insights deployed the first-ever COVID-19 venue bubble solution in a live environment at the Gulf Coast Showcase in Fort Myers, Florida, and #VegasBubble in Las Vegas. The venue bubble was deployed to test, trace and notify over 500 NCAA players, coaches and staff that attended the tournament.

Loop’s Personalized Engagement Platform

Loop Insights’ personalized engagement platform leverages the power of the company’s technology to provide retail operators with an automated marketing platform focused on delivering the right marketing to the right customers to optimize retail engagement.

By leveraging the power of the Wallet pass functionality found on all Android and iOS devices, Loop establishes a direct line of communication with consumers, allowing merchants to provide an AI-personalized marketing experience designed to drive spending and encourage brand loyalty through rewards and other promotions.

Like the digital credit cards or boarding passes that use Wallet pass technology, Loop Insights’ engagement platform provides a seamless user experience without the need to download an additional application. Consumers receive automated promotions and discounts that can be personalized based on user data.

Loop’s Real-Time Insights Platform

By aggregating retail information about consumers and their preferences, Loop’s Insights platform takes the guesswork out of decision making for retailers. Loop’s Insights platform aggregates retail performance data, recording 100% of each transaction before delivering insights and analytics regarding macro and micro buying trends, consumer behavior and optimization opportunities.

As part of its Insights offering, Loop provides AI-based forecasting, modeling and inventory management services to retailers with the ability to integrate third-party data services such as foot traffic and weather.

Loop Insights Devices and Technologies

Loop Insights has developed a line of simple, yet powerful technologies designed to transform industries through the power of IoT technologies and artificial intelligence. The company offers fully automated plug-and-play platforms that can seamlessly integrate and enhance clients’ existing operational infrastructure. The company’s devices are designed to work together seamlessly on top of its enterprise-level cloud infrastructure, providing clients in the retail, entertainment and hospitality industries with the ability to easily optimize their operations.

Fobi

Fobi is an IoT device designed to seamlessly integrate into any existing point of sale or customer management infrastructure. It collects 100% of transactional data and then connects this data to other data points, enabling optimization through AI and data-driven insights.

Loop Insights’ cloud-based AI is designed to aggregate an organization’s data, optimizing the information so it is actionable and easy to use. The Fobi device is hardware agnostic and seamlessly connects with existing points of sale or customer relationship management infrastructure, physically or digitally.

By aggregating an organization’s entire dataset, Fobi is able to merge transactional and behavioral data with customer data to create 360-degree customer profiles, enabling highly-personalized, omnichannel marketing strategies across a number of platforms including email, SMS, paper receipts and the company’s proprietary Wallet pass technology. Loop’s data aggregation service is supported by Amazon Web Services, providing clients with the digital infrastructure and security necessary to protect their data.

SmarTap

SmarTap is a Near Field Communication (NFC) device that enables consumers to “tap” to check-in to locations using their smartphone’s NFC compatibility, enabling contactless customer engagement through the use of Wallet pass technology. By leveraging the functionality of the Wallet pass technology found on Android and iOS devices, Loop is able to drive engagement and provide personalized, data-driven insights without the need for an additional application.

Loop’s SmarTap device can connect to the Loop cloud via LTE or Wi-Fi, allowing retailers to securely transfer encrypted data from wherever their businesses operates.

Loop Cloud

The Loop Cloud brings together datapoints from its Fobi and SmarTap devices to create a unified database for the company and its clients. Instead of individual tills and stores generating their own unique datasets, Loop Insights aggregates data together from a number of sources, creating a complete picture of a client’s retail environment.

By hosting this database in the cloud, Loop Insights provides its clients with more accessible and actionable data that can be accessed from anywhere. Additionally, the Loop cloud allows for real-time monitoring, and its API can be directly integrated into existing PoS systems.

When paired with Loop’s Fobi and SmarTap devices, the Loop Cloud allows for businesses to transform their edge-based legacy systems into a unified database that can be accessed from anywhere.

Uklipz

Expected to launch in January 2021, Loop Insights’ latest product offering, Uklipz, is a next-generation platform that enables consumers to create verified video reviews that can be purchased, analyzed and leveraged by brands to drive engagement and sales.

The addition of Uklipz marks an important milestone for the company, because it further strengthens its product portfolio by providing a reliable solution in the massive but problematic consumer review industry, as Anson explained in a November 2020 news release (https://ibn.fm/YpNlR). He added that the company expects this platform to become a very valuable asset and a significant source of revenue in 2021.

Market Outlook

Loop Insights’ integrated technology solutions and its recent advances in providing end-to-end COVID-19 solutions position the company for significant growth opportunities in the expanding IoT market. According to MarketsandMarkets research, the global IoT sector is expected to reach $561 billion by 2022, up from $180.6 billion in 2017. This market growth can be attributed to an increase in cloud platform adoption and a reduction of costs (https://ibn.fm/1BIPB) which Loop is driving through its engagement and insights platforms.

According to Loop Insights’ August 2020 investor presentation, its innovative solutions open the door to multiple opportunities in additional sectors, including but not limited to:

• Brick and mortar retail – an estimated value of $31,880 billion by 2023 (Mordor Research)
• Sports and entertainment – an estimated value of $614.1 billion by 2022 (The Business Research Company)
• Telecom partnerships – an estimated value of $3,435.2 billion by 2022 (The Business Research Company)
• Casino gaming – an estimated value of $565.4 billion by 2022 (Research and Markets)
• Cannabis – an estimated value of $66.3 billion by 2025 (Grandview Research Inc.)

Management Team

Rob Anson is the Chief Executive Officer and Chairman of Loop Insights. He has also served, since October 2017, as the Chief Executive Officer and Founder of Fobisuite Technologies Inc., a private British Columbia technology company. In a prior role, Anson was the Founder and Chief Executive Officer of One Team Media, a private Vancouver-based media company with digital and television production assets.

Abbey Abdiye is Chief Financial Officer of Loop Insights. He is a Chartered Professional Accountant (CPA) who has served as Chief Financial Officer for a range of public companies throughout his extensive career. Before obtaining his CPA, he received a Bachelor of Business Administration from Simon Fraser University and completed his Co-Op Education Certificate.

Gavin Lee is the company’s Chief Operating Officer. He has over 20 years of experience with global consumer products, with expertise in building top-performing sales teams, brand management, operational excellence and consumer insights. Lee has a strong business understanding and a background in improving salesforce effectiveness. His experience ranges from small entrepreneurial brands to multi-million-dollar global leaders in a variety of marketing segments.

Casey Matson-DeKay is Chief Technology Officer of Loop Insights. He previously held the same position at Fobisuite Technologies, from January 2017 until January 2018. Matson-DeKay has been a developer and information technology consultant for various enterprises. He has been involved with the core technologies utilized by Loop Insights for nearly a decade.

Loop Insights Inc. (RACMF), closed Wednesday's trading session at $1.61, off by 25.977%, on 681,737 volume with 751 trades. The stock's 52-week low/high is $0.000000999/$2.33990001.

Recent News

• InvestorNewsBreaks - Loop Insights Inc. (TSXV: MTRX) (OTCQB: RACMF) Enters Strategic Partnership to Globally Expand 'Travel Bubble' Solution
• InvestorNewsBreaks - Loop Insights Inc. (TSXV: MTRX) (OTCQB: RACMF) to Commence with Uplist, Dual-List Applications
• InvestorNewsBreaks - Loop Insights Inc. (TSXV: MTRX) (OTCQB: RACMF) Announces Launch of New Product into Telus Corporation's (TSX: T) (NYSE: TU) IoT Marketplace

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, strengthened its executive team with the appointment of two proven sales and marketing figures. The two management additions include Amy Griffith, the new vice president of strategy and business development, who will lead the development of strategic and tactical initiatives (https://ibn.fm/Stz6j), and Stuart Bernstein, the new vice president of marketing, who will be responsible for BRSF’s marketing strategy (https://ibn.fm/yfZYU).

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

• NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

• NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

• NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
• NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

• Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
• An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Wednesday's trading session at $1.475, off by 4.8387%, on 2,277 volume with 4 trades. The average volume for the last 3 months is 3,863 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

• Brain Scientific Inc. (BRSF) New Management to Play Key Role in Advancing Commercialization, Growing Revenue
• Coronavirus May Be Worsening Mental Health Conditions in Nursing, Pregnant Women
• Brain Scientific Inc. (BRSF) Well Positioned Within Growing EEG Equipment Market

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Clean Power Capital (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) was featured today in a publication from InvestorWire, examining how, while President Donald Trump’s administration has attempted to move the United States away from global climate change science efforts to boost alternatives to the petroleum fuel standard, the apparent victory of President-elect Joseph Biden (which, in a contested election, will be settled between Dec. 14 and Jan. 6 as electors’ votes are counted (https://ibn.fm/JWII5) signals a new impetus by the nation to advance renewable fuels’ potential.

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Wednesday's trading session at $1.081, off by 7.305%, on 177,722 volume with 150 trades. The stock's 52-week low/high is $0.0315/$1.75.

Recent News

• PowerTap, An Investee Company Of Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF), Sets Sights on Developing Hydrogen Fuel Market
• Hydrogen-Powered Vehicles Usher in New Era of Transportation
• InvestorNewsBreaks - Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Talks PowerTap Carbon Capture System

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) was featured today in the 420 with CNW by CannabisNewsWire. It may be conceivable that everyone has a phobia; some are small while others can be crippling. Remember Ron Weasley and his phobia of spiders? While some people are only slightly fazed by their phobias, which are defined as irrational fears, others are significantly impacted by them, going as far as to avoid doing certain things or going to specific places because of them.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Wednesday's trading session at $1.08, off by 2.7027%, on 1,915,464 volume with 3,700 trades. The average volume for the last 3 months is 1,644,400 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

• 420 with CNW - Cannabis May Help Alleviate Your Phobias
• National Brands Vie for CBD Dominance
• 420 with CNW - How to Select a Delivery Service for Your Medical Marijuana

Pure Extracts Technologies Corp. (CSE: PULL)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL).

Pure Extracts Technologies Corp. (CSE: PULL) was featured today in a publication from PsychedelicNewsWire, examining how, in last month’s election, Oregon became the first U.S. state to legalize psychedelic mushroom use for various therapy purposes. Oregon Gov. Kate Brown is now implementing measures to kick off the program by accepting applications for board members. The board’s role will be to work out the process for regulating psychedelic treatment access. Also today, the company was featured in a publication from PsychedelicNewsWire, examining how Pure Extracts Technologies recently signed a letter of intent with the Nutraceutical Medicine Company Inc. (“PURICA”). PURICA owns and distributes the PURICA product line of full-spectrum, mushroom-derived wellness products. Pure Extracts anticipates the PURICA brand will support PULL’s expansion into the functional mushroom sector. For the past two decades, PURICA has offered natural and whole food products that are backed by science. To view the full press release, visit http://ibn.fm/vPh1t

Pure Extracts Technologies Corp. (CSE: PULL), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (CSE: PULL), closed Wednesday's trading session at $0.69, off by 6.76%, on 1,160,000 volume with 494 trades. The average volume for the last 3 months is 314,315 and the stock's 52-week low/high is $0.47/$0.78.

Recent News

• Governor of Oregon Appoints Advisory Board to Begin Psilocybin Mushroom Therapy Regulation
• PsychedelicNewsBreaks - Pure Extracts Technologies Corp. (CSE: PULL) Announces LOI with Owner of PURICA(TM) Brand of Wellness Product
• 420 with CNW - UN Votes to Remove Marijuana from Schedule IV Drug Classification

Innovative Payment Solutions Inc. (OTCQB: IPSI)

The QualityStocks Daily Newsletter would like to spotlight Innovative Payment Solutions Inc. (OTCQB: IPSI).

Innovative Payment Solutions (OTCQB: IPSI) is a digital payment technology service company that provides cutting-edge solutions for consumers and service providers. Leveraging its proprietary fintech payment architecture, the company is focused on building a 21st century payment platform. IPSI has spent the last five years perfecting its payment platform through its Mexico-based operations, which facilitate over two million users. To view the full article, visit https://ibn.fm/O068l

Innovative Payment Solutions Inc. (OTCQB: IPSI) is a digital payment technology service company offering cutting-edge solutions for consumers and service providers. It is focused on building a 21st century payment platform based on its proprietary fintech payment architecture.

Incorporated in 2015 and headquartered in Northridge, California, the company has spent the last five years perfecting its payment platform through its operations in Mexico, which still facilitate over two million users.

IPSI’s new business structure will use the latest technology, including blockchain and an e-wallet, to provide consumers the ability to make payments worldwide. The company’s innovative ecosystem will include multiple devices, such as POS terminals, mobile applications and self-service kiosks, offering alternative payment methods to meet the needs of unbanked and underbanked consumers.

IPSI Kiosk Platform

The IPSI Kiosk platform strategy aims to provide simple payment solutions and low-cost financial services for consumers and businesses. These kiosks offer access to digital payments for the unbanked and underbanked, allowing for remittance, merchant payments, microloans and other financial services.

The kiosk enables new features and transaction modules to be added and implemented easily, leveraging a flexible, open architecture to minimize costs. Current services provided by the kiosks include bill pay and cellphone top-up. Additional features are currently in development, including payday loans, gaming, auto insurance, title loans, lottery, international remittance, a mobile app and an e-wallet.

Already linked to Mexico’s largest service providers, the IPSI network is expected to add over 150 services for payment, including mobile networks, cable providers, home lenders, banks and microlenders. In 2019, IPSI’s kiosk network processed roughly 4.5 million transactions in Mexico totaling over $17 million.

The company currently has 50 kiosks that it intends to install at retail locations in Southern California. It also plans to deploy kiosks in other states.

IPSI Kiosk Channel Value

The IPSI Kiosk provides value for businesses and consumers.

For businesses, the IPSI Kiosk:

• Serves as an additional revenue source;
• Attracts new traffic and potential customers;
• Offers remote software updates and monitoring, making the kiosks low maintenance;
• Is easy to use, with little need for customer service intervention; and
• Requires minimal staff training and overhead.

For consumers, the IPSI Kiosk:

• Offers a more comfortable alternative for making payments for cash-dependent unbanked individuals and those uncomfortable with online payments and
• Is accessible 24/7 for bill payment services.

The IPSI Kiosk also provides add-on services that further its value proposition for both businesses and consumers. These include second screen and targeted advertisement options, payday loans, check deposits, prepaid cards and checkout services.

IPSI Coin

IPSI is currently working on plans to launch its own stable IPSI Coin and has retained Horizons Law and Consulting Group to advise on its stable coin creation. The company plans for IPSI Coin to be backed by the U.S. dollar and administered by an independent custodian to ensure transparency and stability.
The creation of the coin will enable customers to send payments directly to over 200 service providers in Mexico and transfer funds in a matter of minutes via the self-service kiosks to be implemented in Southern California.

“The fintech industry is undergoing a massive shift with the introduction of artificial intelligence, everchanging distribution models, fee diversion and digital payments,” IPSI CEO William Corbett stated in a news release (https://ibn.fm/wwtBV). “We are focused on providing a comprehensive solution in the digital payment arena for those who need it most. Our goal is to provide the millions of unbanked and underbanked as well as banked consumers in California, a cost efficient and convenient method to make payments and remittances with instant settlement.”

Digital Payment Market Outlook

In 2018, the global digital payment market was estimated at $43.5 billion. It is expected to register a CAGR of 17.6% through 2025, reaching a forecast market size of $132.5 billion, according to Grandview Research (https://ibn.fm/pLTUt).

The growth is expected to be led by expanding use of smartphones, e-wallet payment solutions and the introduction of unbanked payment solutions to the market, offering companies such as IPSI significant opportunities for expansion.

Management Team

William Corbett is the CEO and a Director of IPSI. He has 30 years of experience financing and advising development and growth stage tech and biotech companies. Before IPSI, he was the founder and CEO of California-based Digital Power Lending. Corbett gained experience as a managing director during his time with Paulson Investment Co. and in senior banking and top producer roles at Lehman Brothers and Bear Stearns. He was a co-founder of the San Francisco and PIPE pioneer boutique investment bank, The Shemano Group. He has raised over $2 billion during his extensive career.

Andrey Novikov serves as IPSI’s Chief Technical Officer and Chief Operating Officer. He is the former VP of Global Business Development of Qiwi PLC (NASDAQ: QIWI). Leveraging extensive knowledge of the industry, Novikov played a lead role in the development of Qiwi startups in China, Mexico, India, Brazil, Argentina, Chile, Peru and other countries.

James W. Fuller holds a Director position at IPSI. He is the former chairman of San Francisco think tank Pacific Research Institute. He is a board member for The International Institute of Education, a member of the Pacific Council for International Policy, and a former member of the Committee of Foreign Relations and the board of trustees of the University of California – Santa Cruz. He is the former Senior Vice President of the New York Stock Exchange and was responsible for corporate development, marketing, regulation oversight, research, corporate listing and public affairs.

Innovative Payment Solutions Inc. (IPSI), closed Wednesday's trading session at $0.022, off by 26.6667%, on 781,523 volume with 00 trades. The average volume for the last 3 months is 000,000 and the stock's 52-week low/high is $0.0091/$0.068800002.

Recent News

• CryptoNewsBreaks - Why Innovative Payment Solutions Inc. (IPSI) Is 'One to Watch'
• CryptoNewsBreaks - Innovative Payment Solutions Inc. (IPSI) Announces Strategic Advisory Board Appointment
• Innovative Payment Solutions Inc. (IPSI) Is 'One to Watch'